INSMED INC Current Liabilities
INSMED INC (INSM) had Current Liabilities of $438.74 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-06
- 2026-06-30: Liabilities, Current $438.74M.
- 2026-03-31: Liabilities, Current $361.01M.
- 2025-12-31: Liabilities, Current $468.87M.
- 2025-09-30: Liabilities, Current $417.21M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $438.74M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $361.01M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $468.87M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $417.21M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $311.68M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $239.23M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $297.53M 10-K · filed 2026-02-19 |
| 2024-09-30 | $259.19M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $524.15M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $420.86M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $225.63M 10-K · filed 2025-02-20 |
| 2023-09-30 | $196.73M 10-Q · filed 2023-10-26 |
| 2023-06-30 | $204.26M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $187.98M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $190.24M 10-K · filed 2024-02-22 |
| 2022-09-30 | $137.65M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $113.82M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $125.25M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $135.17M 10-K · filed 2023-02-23 |
| 2021-09-30 | $112.50M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $99.66M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $81.40M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $118.81M 10-K · filed 2022-02-17 |
| 2020-09-30 | $83.90M 10-Q · filed 2020-10-29 |
| 2020-06-30 | $78.75M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $71.53M 10-Q · filed 2020-04-30 |
| 2019-12-31 | $85.24M 10-K · filed 2021-02-25 |
| 2019-09-30 | $85.39M 10-Q · filed 2019-10-30 |
| 2019-06-30 | $86.03M 10-Q · filed 2019-08-01 |
| 2019-03-31 | $94.25M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $79.73M 10-K · filed 2020-02-25 |
| 2018-09-30 | $57.42M 10-Q · filed 2018-10-30 |
| 2018-06-30 | $45.64M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $34.81M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $44.66M 10-K · filed 2019-02-22 |
| 2017-09-30 | $28.77M 10-Q · filed 2017-11-02 |
| 2017-06-30 | $26.27M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $23.27M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $27.99M 10-K · filed 2018-02-23 |
| 2016-09-30 | $23.46M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $32.32M 10-Q · filed 2016-08-04 |
| 2016-03-31 | $25.54M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $22.26M 10-K · filed 2017-02-23 |
| 2015-09-30 | $46.70M 10-Q · filed 2015-11-06 |
| 2015-06-30 | $43.07M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $41.13M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $19.63M 10-K · filed 2016-02-25 |
| 2014-09-30 | $21.28M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $21.82M 10-Q · filed 2014-08-06 |
| 2014-03-31 | $20.00M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $16.46M 10-K · filed 2015-02-27 |
| 2013-09-30 | $19.82M 10-Q · filed 2013-11-05 |
| 2013-06-30 | $18.10M 10-Q · filed 2013-08-06 |
| 2013-03-31 | $20.27M 10-Q · filed 2013-05-07 |
| 2012-12-31 | $15.75M 10-K · filed 2014-03-06 |
| 2012-09-30 | $6.54M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $6.49M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $4.14M 10-Q · filed 2012-05-08 |
| 2011-12-31 | $4.48M 10-K · filed 2013-03-18 |
| 2011-09-30 | $3.68M 10-Q · filed 2011-11-09 |
| 2011-06-30 | $3.49M 10-Q/A · filed 2011-08-08 |
| 2010-12-31 | $3.34M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |